Literature DB >> 25748683

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.

E Brissot1,2,3,4, A Clavert3, N Blin3, V Roland3, T Guillaume3,4, V Dubruille3, B Mahe3, T Gastinne3, S Le Gouill3,4, B Gaugler5,6,7, P Moreau3, M Mohty1,2,3,4,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25748683     DOI： 10.1038/leu.2015.64

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

2.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

3.  Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.

Authors:  Brigitte Neuber; Isabelle Herth; Claudia Tolliver; Stefan Schoenland; Ute Hegenbart; Dirk Hose; Mathias Witzens-Harig; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Michael Hundemer
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

4.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Authors:  F E Davies; N Raje; T Hideshima; S Lentzsch; G Young; Y T Tai; B Lin; K Podar; D Gupta; D Chauhan; S P Treon; P G Richardson; R L Schlossman; G J Morgan; G W Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

5.  Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.

Authors:  Kimberly Noonan; Lakshmi Rudraraju; Anna Ferguson; Amy Emerling; Marcela F Pasetti; Carol A Huff; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2012-01-12       Impact factor: 12.531

6.  Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

Authors:  A K Gandhi; J Kang; L Capone; A Parton; L Wu; L H Zhang; D Mendy; A Lopez-Girona; T Tran; L Sapinoso; W Fang; S Xu; G Hampton; J B Bartlett; P Schafer
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

7.  lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.

Authors:  Lei Wu; Mary Adams; Troy Carter; Roger Chen; George Muller; David Stirling; Peter Schafer; J Blake Bartlett
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

8.  Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.

Authors:  Brenda De Keersmaecker; Karel Fostier; Jurgen Corthals; Sofie Wilgenhof; Carlo Heirman; Joeri L Aerts; Kris Thielemans; Rik Schots
Journal:  Cancer Immunol Immunother       Date:  2014-06-20       Impact factor: 6.968

9.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

10.  Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.

Authors:  Ole Audun Werner Haabeth; Kristina Berg Lorvik; Clara Hammarström; Ian M Donaldson; Guttorm Haraldsen; Bjarne Bogen; Alexandre Corthay
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919
View more
  5 in total

Review 1.  Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.

Authors:  Giulia Di Lullo; Magda Marcatti; Silvia Heltai; Cristina Tresoldi; Anna Maria Paganoni; Claudio Bordignon; Fabio Ciceri; Maria Pia Protti
Journal:  Front Immunol       Date:  2019-01-21       Impact factor: 7.561

Review 3.  Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.

Authors:  Marco Cippitelli; Helena Stabile; Andrea Kosta; Sara Petillo; Angela Gismondi; Angela Santoni; Cinzia Fionda
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

4.  Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Authors:  Karel Fostier; Jo Caers; Nathalie Meuleman; Katrijn Broos; Jurgen Corthals; Kris Thielemans; Rik Schots; Brenda De Keersmaecker
Journal:  Oncotarget       Date:  2018-04-17

Review 5.  Ikaros Proteins in Tumor: Current Perspectives and New Developments.

Authors:  Ruolan Xia; Yuan Cheng; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  Front Mol Biosci       Date:  2021-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.